EXHIBIT 99.1

FOR IMMEDIATE RELEASE







For Danisco:

Investor Relations, Michael von Bulow, tel.: +45 3266 2912.

Media Relations, Nathalie Weber,  tel.: +45 3266 2913


For Genencor:

Investor Relations, Tom Rathjen, tel: +1-650-846-7500

Media Relations, Jack Huttner tel:  +1-585-256-5200





DANISCO TO ACQUIRE GENENCOR

COPENHAGEN, Denmark and PALO ALTO, California, January 27, 2005 - Danisco A/S
(Copenhagen Stock Exchange) ("Danisco"), one of the world's largest producers of
food ingredients, and Genencor International, Inc. (Nasdaq: GCOR) ("Genencor"),
a diversified biotechnology company that develops and delivers innovative
products and services into the health care, agri-processing, industrial and
consumer markets, today jointly announced that they have signed a definitive
agreement for Danisco to acquire all of the outstanding shares of common stock
of Genencor, other than those held by Danisco, Eastman Chemical Company
("Eastman") or their respective subsidiaries, for $19.25 per share in cash.

In connection with the definitive agreement with Genencor, Danisco has entered
into a definitive stock purchase agreement with Eastman under which Danisco will
acquire all of the outstanding shares of common stock of Genencor held by
Eastman for $15 per share in cash and all of the outstanding shares of preferred
stock of Genencor held by Eastman for $44 million in cash. Danisco and Eastman
currently each own approximately 42% of Genencor's outstanding shares of common
stock and 50% of Genencor's outstanding shares of preferred stock.

"Being an advanced and recognised biotechnology company, Genencor will expand
Danisco's knowledge base significantly and broaden our access to an important
new business area, industrial enzymes," said Alf Duch-Pedersen, Chief Executive
Officer of Danisco.

"Our two companies know each other well and the synergy is obvious," said JJ
Bienaime, Chairman and Chief Executive Officer of Genencor. "Together, we will
have the depth and the reach to achieve the vision we've had for our business."

The acquisition of the shares of Genencor's common stock for $19.25 per share
will be effected by means of a cash tender offer for all of the outstanding
shares of common stock of Genencor, other than those held by Danisco and its
subsidiaries, followed by a merger in which all Genencor stockholders, other
than Danisco and its subsidiaries, who have not tendered their shares will
receive the same per share price. The acquisition agreement is subject to
certain conditions, including the tender of a majority of the outstanding shares
of common stock of Genencor other than those held by Danisco, Eastman, the
officers and directors of Genencor and its subsidiaries and the respective
affiliates of each of the foregoing, receipt of regulatory approvals and other
conditions. Subject to those conditions, Danisco and Genencor currently expect
the acquisition to be completed by May 31, 2005.



A special committee comprised of independent directors of Genencor has reviewed
the transaction on behalf of the Genencor stockholders unaffiliated with Danisco
and Eastman. Upon the recommendation of the special committee, the board of
directors of Genencor has approved the acquisition agreement and the
transaction.

About Danisco

Danisco develops and produces food ingredients, sweeteners and sugar. The group
employs around 9,000 people in some 40 countries and reported net sales of DKK
16.4 billion (USD 2.9 billion) in 2003/04. Danisco's broad product portfolio
includes emulsifiers, stabilisers, cultures, flavours and sweeteners such as
xylitol and fructose. The majority of these ingredients are produced from
natural raw materials and contribute, for instance, to improving the texture in
bread, ice cream, yoghurt and other products. Danisco is also one of the largest
and most efficient sugar producers in Europe.

About Genencor

Genencor International is a diversified biotechnology company that develops and
delivers innovative products and services into the health care, agri-processing,
industrial and consumer markets. Using an integrated set of technology
platforms, Genencor's products deliver innovative and sustainable solutions to
improve the quality of life. Genencor traces its history to 1982 and has grown
to become a leading biotechnology company. Genencor has principal offices in
Palo Alto, California; Rochester, New York; and Leiden, The Netherlands.

Notice to Read Tender Offer Materials

The description contained herein is neither an offer to purchase nor a
solicitation of an offer to sell shares of Genencor. At the time the tender
offer is commenced, an indirect wholly-owned subsidiary of Danisco ( "Danisco's
acquisition subsidiary") and Danisco intend to file a Tender Offer Statement on
Schedule TO with the Securities and Exchange Commission containing an offer to
purchase, forms of letters of transmittal and other documents relating to the
transaction and Genencor intends to file a Solicitation/Recommendation Statement
on Schedule 14D-9 relating to the transaction with the Securities and Exchange
Commission. Danisco's acquisition subsidiary, Danisco and Genencor intend to
mail these documents to the stockholders of Genencor. Genencor and Danisco also
intend to file a Transaction Statement on Schedule 13E-3 with the Securities and
Exchange Commission relating to the transaction. These documents will contain
important information about the transaction and stockholders of Genencor are
urged read them carefully when they become available. Stockholders of Genencor
will be able to obtain a free copy of these documents (when they become
available) at the website maintained by the Securities and Exchange Commission
at www.sec.gov. In addition, stockholders will be able to obtain a free copy of
these documents (when they become available) from Danisco by contacting Danisco
at: Langebrogade 1, P.O. Box 17, DK-1001 Copenhagen K, Denmark, attention:
Investor Relations, or from Genencor by contacting Genencor at: 925 Page Mill
Road, Palo Alto, CA 94304, attention: Investor Relations.


                                       ###